Thursday January 18th 2018

FDA gives final approval to Perrigo’s ANDA for repaglinide tablets 1 mg and 2 mg

Perrigo Company plc today announced that it has received final approval from the U.S. Food & Drug Administration for its abbreviated new drug application for repaglinide tablets 1 mg and 2 mg, the generic equivalent to Prandin Tablets (repaglinide tablets) and has commenced shipment of product. Perrigo previously launched the 0.5 mg strength in 2013.

Original source: 

FDA gives final approval to Perrigo’s ANDA for repaglinide tablets 1 mg and 2 mg

Leave a Comment

More from category

6,000-year-old track record for healing leaky gut
6,000-year-old track record for healing leaky gut

When I was traveling in India, I had the privilege of studying Ayurvedic medicine with traditional Master Healers. [Read More]

Study shows high-salt diet causes dementia in mice
Study shows high-salt diet causes dementia in mice

A high-salt diet reduces resting blood flow to the brain and causes dementia in mice, according to a new study by [Read More]

What you should know about neurosarcoidosis
What you should know about neurosarcoidosis

A look at neurosarcoidosis, an inflammatory disease that can affect most organs in the body. Included is detail on [Read More]

Depression and fatigue in multiple sclerosis: relation to exposure to violence and cerebrospinal fluid immunomarkers – Brenner P, Granqvist M, K…
Depression and fatigue in multiple sclerosis: relation to exposure to violence and cerebrospinal fluid immunomarkers – Brenner P, Granqvist M, K…

Multiple sclerosis (MS) is a neuroinflammatory condition characterized by chronic dysregulation of immune responses [Read More]

Your NEJM Group Today: MS Review / HIV PrEP for Women / Texas Medical Director Opportunity
Your NEJM Group Today: MS Review / HIV PrEP for Women / Texas Medical Director Opportunity

Here's what we selected for you today: NEJM Clinical Practice Center: Review: A number of interventions to modify the [Read More]